Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | UBE2M | P61081 | 11/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 11/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800145 | 0.93 | LMNA (0.35) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2799822 | 0.92 | THRB (0.38) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL5040337 | 0.87 | THRB (0.45) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2796082 | 0.86 | KCNH2 (0.39) | THRBUBE2MDCUN1D1HTR2AKCNH2 | |
| SCHEMBL2795743 | 0.83 | UBE2M (0.39) | THRBUBE2MDCUN1D1LMNA | |
| SCHEMBL2796269 | 0.83 | KCNH2 (0.47) | THRBUBE2MDCUN1D1LMNAHTR2A | |
| SCHEMBL2800239 | 0.82 | LMNA (0.40) | UBE2MDCUN1D1LMNA | |
| SCHEMBL2797191 | 0.82 | UBE2M (0.38) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2800189 | 0.82 | UBE2M (0.38) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2797887 | 0.82 | KCNH2 (0.36) | THRBUBE2MDCUN1D1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | THRB 2956/4885UBE2M 2433/4885DCUN1D1 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.